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StriatumDopamine function is disturbed in Parkinson's disease (PD), but whether and how release of dopamine from
surviving neurons is altered has long been debated. Nicotinic acetylcholine receptors (nAChRs) on dopamine
axons powerfully govern dopamine release and could be critical contributing factors. We revisited whether fun-
damental properties of dopamine transmission are changed in a parkinsonian brain and tested the potentially
profound masking effects of nAChRs. Using real-time detection of dopamine in mouse striatum after a partial
6-hydroxydopamine lesion and under nAChR inhibition, we reveal that dopamine signals show diminished
sensitivity to presynaptic activity. This effect manifested as diminished contrast between DA release evoked by
the lowest versus highest frequencies. This reduced activity-dependence was underpinned by loss of short-
term facilitation of dopamine release, consistentwith an increase in release probability (Pr). With nAChRs active,
the reduced activity-dependence of dopamine release after a parkinsonian lesion was masked. Consequently,
moment-by-moment variation in activity of nAChRs may lead to dynamic co-variation in dopamine signal
impairments in PD.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
In PD, degeneration of midbrain dopamine (DA) neurons causes
progressive loss of striatal DA. Motor deﬁcits occur when neurodegen-
eration exceeds ~60% suggesting that compensatorymechanismsmain-
tain DA function (Zigmond et al., 1990). Whether changes in release or
reuptake mediate this compensation has been debated. Early studies
reported enhanced DA synthesis (tyrosine hydroxylase, TH activity)
and turnover (altered brain DA metabolites) (Agid et al., 1973; Altar
et al., 1987; Hornykiewicz and Kish, 1987; Stachowiak et al., 1987),
hypothesising that increased release from the remaining release sites
compensates for reduced axonal density (Garris et al., 1997; Zigmond
et al., 1990). By contrast, voltammetry studies which can distinctlya2+]o, extracellular calcium
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ect.com).
. This is an open access article underresolve release and reuptake ﬁnd that release is unchanged in the par-
kinsonian rodent brain but that reduced uptake compensates for the
diminished number of DA release sites through a process of ‘passive sta-
bilization’ (Bergstrom and Garris, 2003; Bezard et al., 2000; Garris et al.,
1997). Additionally, whilst direct evidence of increased release is lack-
ing in voltammetry studies, one study has found that sustainability of
DA release is enhanced after lesion (Bergstrom et al., 2011).
We have recently identiﬁed that striatal DA release is under potent
control by striatal acetylcholine, which is primarily released from cho-
linergic interneurons (ChIs) and acts at nAChRs on DA axons. Compared
to DA release when nAChRs are active, DA release when nAChRs are in-
active shows a reduced probability of release and a stronger sensitivity
to the ﬁring frequency of DA neurons (Cragg, 2006; Rice and Cragg,
2004; Zhang and Sulzer, 2004). By contrast, upon activation of nAChRs,
DA Pr is apparently increased, and sensitivity of DA release to DAneuron
ﬁring frequency is limited (Rice and Cragg, 2004; Cragg, 2006).
Furthermore, DA release can even be driven directly by activation
of ChIs, without the need for DA neuron activity (Threlfell et al.,
2012). Therefore, the dynamic availability of extracellular DA is pre-
dicted to be highly variable depending on the activity of both DA
neurons and ChIs (Cragg, 2006). In PD, altered DA release might be
determined by adaptations in either of these two neuron types. Here,
we identify novel adaptations to DA release after a parkinsonian lesion
that are distinct from the potent inﬂuence of ChIs and which can be
masked by nAChR activation.the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Animals and surgery
Male C57BL6J mice (8–18 weeks, Charles River, UK) were kept on
a 12 h light:dark cycle (lights on at 7 am) and had free access to lab
chow, water and nesting materials. All animal procedures were
carried out in accordance with the Animals (Scientiﬁc Procedures)
Act (1986). Mice were anaesthetised with isoﬂurane (4 then 1.6–
2.5%) and local anaesthesia was administered at the incision site
(bupivacaine 0.1 mg/kg s.c.). Unilateral craniotomy was performed
and 6-hydroxydopamine solution was injected into the SNc using a
graduated micropipette (1 μl of a 0.9% saline solution containing
4 μg/μl 6-OHDA [Sigma-Aldrich] and 0.02% acetic acid over 5–20 min;
AP −3.5; ML ±1.0 from Bregma, DV −4.1 mm from brain surface).
The pipette waswithdrawn after a further 10min tominimise backﬂow
up the injection tract. Palatable food (forage mix, jelly) and heat were
provided routinely during the ﬁrst 48 h, and as necessary during the
remainder of the time after surgery. No gross behavioural changes
were observed after 6-OHDA lesion. All further reference of lesion refers
to this 6-OHDA-induced lesion.
Slice preparation and fast scan cyclic voltammetry (FCV)
At 21±5 days post-surgery, micewere killed by cervical dislocation
and the brain dissected and sliced (300 μm) in ice-cold HEPES ringer (in
mM: 120NaCl, 5 KCl, 20NaHCO3, 6.7 HEPES acid, 3.3HEPES salt, 2 CaCl2,
2 MgSO4, 1.2 KH2PO4 and 10 glucose saturated with 95% O2/5% CO2)
using a Leica VT1000S vibratome. After ≥1 h at room temperature,
slices were transferred to a recording chamber and superfused with
bicarbonate-buffered artiﬁcial CSF (aCSF) at ~1.5 ml/min and 30–
32 °C (in mM: 124 NaCl, 3.7 KCl, 26 NaHCO3, 2.4 CaCl2, 1.3 MgSO4,
1.3 KH2PO4, and 10 glucose saturated with 95% O2/5% CO2).
All DA recordings were made using a Millar Voltammeter (Julian
Millar, Barts and the London School of Medicine and Dentistry, UK) as
described previously (e.g., Threlfell et al., 2012). Voltammograms were
obtained by scanning with a triangular waveform (−0.7 to +1.3 V to
−0.7 V versus Ag/AgCl switching to 0 V between scans; 800 V/s;
8 Hz). Evoked extracellular DA concentration ([DA]o) was measured
using FCV with carbon ﬁbre microelectrodes (CFMs) constructed in-
house (ﬁbre tip diameter, ~7 μm; exposed ﬁbre length, 50–100 μm)
and positioned ~100 μm into the tissue. Electrode calibrationswere per-
formed after recordings for each electrode using 2 μM DA in Ca2+-
appropriate aCSF.
Experiments were designed so that lesioned and non-lesioned
experiments were carried out in the same animal (except in [Ca2+] re-
sponse experiments). Each non-lesioned recording was carried out in
the equivalent anatomical location as a paired lesioned recording from
that animal.
Electrical stimulation
A concentric bipolar stimulating electrode (FHC, Bowdoinham, ME)
was used to electrically evoke DA release in the striatum. The stimulat-
ing electrodewas positioned on the tissue surface ~50–100 μm from the
CFM. Monophasic stimulus pulses (0.2 ms duration; 0.65 mA) were ap-
plied out-of-phase with FCV scans. Stimuli were repeated at intervals of
2.5min, as single pulses and 5-pulse trains at 5, 10, 25 and 100Hz. Stim-
ulation at 5–25Hzwas chosen to encompass the physiologicalﬁring fre-
quencies commonly reported in DA neurons. Stimulation at 100 Hzwas
chosen as a ‘release-limited frequency’ speciﬁcally for probing the
short-term plasticity of DA release. This method has previously been
published for DA (Cragg, 2003; Rice and Cragg, 2004) and the approach
is a well-established method for interrogating short-term plasticity
mechanisms at glutamate and GABA synapses (e.g., Regehr, 2012;
Thomson, 2000, 2003).Paired pulse experiments
In a subset of experiments, paired-pulse release was explored to as-
sess release probability (Pr). Because release summates during two-
pulse trains, release at the second pulse (P2 release) was calculated by
subtracting single pulse release (P1 release) from paired-pulse release.
P2 release was then divided by P1 release to obtain the paired-pulse
ratio (PPR). Previous studies of glutamate neurons have demonstrated
that as initial Pr increases (i.e., P1 release), P2 release and PPR decrease.
Conversely, when initial Pr is low, P2 release increases and can show
facilitation such that P2 release N P1 release and PPR N 1. Note that
PPR is here expressed as a percentage to maintain consistency through-
out the ﬁgures.
Drug application
Experimental drugsweremade up in stock solutions of 1000–5000×
ﬁnal concentration in water and stored in aliquots at−20 °C until use.
Just prior to use, aliquots were diluted into O2/CO2-saturated aCSF and
bath-applied. In experiments where extracellular [Ca2+] was varied,
measurements were taken in standard aCSF (2.4 mM Ca2+), before
switching to the lowest [Ca2+] solution and working up through the
concentrations.
High performance liquid chromatography
Tissue punches (1 mm diameter) were taken from the striatum of
lesioned and non-lesioned hemispheres of acute slices prepared
from 6-OHDA treated mice. Punches were placed into ice-cold
perchloric acid (0.1 M) and stored at −80 °C until analysis. Tissue
was homogenised using a sonicating probe (pulsed for ~10 s), centri-
fuged (25000 ×g; 15min) and supernatant removed for analysis. Dopa-
mine was separated on a ChromSep C18 reverse-phase column (5 μm;
4.6 × 250 mm; Varian) and detected (Decade SDC; Antec Leyden)
using a glassy carbon working electrode (VT03 Antec Leyden; +0.7 V
vs Ag/AgCl reference). Mobile phase consisted of 13% methanol,
0.12 M NaH2PO4, 0.8 mM EDTA, 2.0 mM octane sulphonic acid, pH 3.2.
Dopamine concentrations were interpolated from known concentra-
tions of dopamine run alongside samples and normalised to protein
content.
Immunohistochemistry
After FCV, acute sliceswere ﬁxed in 4% paraformaldehyde for several
days before re-sectioning (40 μm) and processing for immunohisto-
chemistry. Sectionswere incubated in 0.5% triton in phosphate buffered
saline (PBS) for 30min at room temperature, washed (3 × 10min PBS),
blocked for 30min (PBSwith 0.5% triton, 10% normal goat serum [NGS],
10% foetal calf serum [FCS]) and incubated overnight in primary anti-
body (1:1000; rabbit anti-tyrosine hydroxylase, T8700, Sigma; in PBS
with 0.5% triton, 1% NGS, 1% FCS). The following day, sections were
washed (3 × 10 min PBS), and incubated in secondary antibody
(1:500 goat anti-rabbit, PK6101, Vector Labs; in PBS with 0.5% Triton,
1% NGS, 1% FCS) and visualised using the ABC system (PK6101, Vector
Labs) and VIP peroxidase substrate (SK4600; 3–4 min incubation). Sec-
tions were thenmounted on glass slides, dehydrated and delipidated in
ascending ethanol concentrations (1–2 min each) followed by xylene
(30 min) and glass coverslips were mounted using DePex.
Data analysis and statistics
FCV data were acquired and analysed using Strathclyde Whole
Cell Program (University of Strathclyde, Glasgow, Scotland, UK)
and Microsoft Excel. DA oxidation currents were measured from
background-subtracted voltammograms, converted to concentration
using the calibration factor for that CFM in each solution, and plotted
264 K.A. Jennings et al. / Neurobiology of Disease 82 (2015) 262–268against time to give a transient proﬁle of [DA]o. Triplicate measure-
ments for each stimulation type at each recording site were averaged
to produce a proﬁle per stimulation type. After conﬁrming that lesion
caused a signiﬁcant reduction to evoked [DA]o, data were expressed as
a percentage of [DA]o evoked by a single pulse to allow assessment of
frequency-dependence, PPR, train-length dependence and calcium-
dependence, independent of absolute levels of [DA]o. Mean peak
evoked [DA]o ± SEM were statistically analysed using SPSS 16. Data
were tested for normal distribution using the Shapiro–Wilk test, and
where non-normally distributed, a Box–Cox transformation (Osborne,
2010) was applied to normalise the distribution (λ values listed next
to the statistics where applicable) or, where the data distribution
could not be made normal, a Friedman test was used. Transformed data
were re-tested for normality and analysed with a two-way ANOVA. Sig-
niﬁcant main effects were examined and interactions were interrogated
further with a post hoc protected Fisher's LSD.Fig. 1. Partial lesion of striatal DA changes thedynamic range of DA signals. A, top, A 6-OHDA injec
Friedman test; n = 10 experiments from 5 animals; colours correspond to site illustrated in the
tended clearance phase for DA after a lesion shows reduced DA uptake rate, representative exam
time (F(11,154) = 142, p b 0.001) and lesion (F(1,14) = 24.9, p b 0.001) and a lesion ∗ time interac
evoke comparable peak [DA]o to lesion. C, HPLCmeasurement of reduced tissueDA content after 6
by 1p or 5p at 5–100Hz (vertical lines) in non-lesion control (black) and in the lesion (red) in the
non-lesion (unﬁlled) vs lesion (ﬁlled) from D expressed as % of peak [DA]o evoked by 1p in each
F(3,18)=14.2and pb 0.05 lesion versus non-lesion, Fisher's LSD; data transformed tonormality,λ
in non-lesion (left) and in the lesion (right); and lower, mean peak [DA]o± SEMvs pulse number
in each condition. For both groups n=6 experiments from6 animals. Lesion reduces thepulse nu
and Fwere collected in DHβE (1 μM).Results
nAChR inhibition unmasks a deﬁcit in dynamic properties of DA release
after a partial 6-OHDA lesion
To assess the impact on striatal DA transmission remaining after a
substantial but partial DA lesion, we injected 6-OHDA into the
substantia nigra pars compacta (SNc). We detected evoked DA release
using fast-scan cyclic voltammetry (FCV) in four regions of lesioned cau-
date putamen (dorsomedial, central, ventrolateral and ventromedial)
and showed that evoked [DA]o was reduced to 18–30% of controls
(Fig. 1A). In addition,we conﬁrmed that the fallingphase of theDA tran-
sient was signiﬁcantly extended (indicative of reduced uptake rate; see
Fig. 1B) and tissue DA content was reduced (Fig. 1C), as expected.
Striatal electrical stimulation will activate both dopaminergic axons
and cholinergic neurons, meaning that DA release driven by DA axontion into the SNc reducedmean [DA]o (±SEM) evoked by 1 pulse (Χ2(7)=58.1, ***p b 0.001
bottom). Bottom, reduced tyrosine hydroxylase (TH) staining in dorsal striatum, SNc. B, Ex-
ple. Group statistics (n= 7 experiments from 7 animals) showed signiﬁcant main effect of
tion (F(11,154) = 6.0, p b 0.001). A lower stimulation current was used in non-lesion sites to
-OHDA lesion, t(8)=7.4, ***p b 0.001 T-test.D,Meanproﬁles of [DA]o±SEMvs time evoked
presence of nAChR antagonist DHβE (1 μM). E, Mean peak [DA]o± SEMvs frequency (5p) in
condition, for each group n= 7 experiments from 7 animals (*p b 0.001 frequency ∗ lesion
=0.061). F,Upper,meanproﬁles of [DA]o±SEMvs timeevoked by 1–9pat 100Hz (arrows)
(100Hz) in non-lesion (unﬁlled) vs lesion (ﬁlled) expressed as % of peak [DA]o evoked by 1p
mber dependence of evoked [DA]o (**p b 0.005 lesion F(2,10)=14.6, ANOVA). Data fromD, E
265K.A. Jennings et al. / Neurobiology of Disease 82 (2015) 262–268activity aswell as by nAChR activationwill contribute to our [DA]o signal
(Threlfell et al., 2012; Wang et al., 2014). Therefore, we inhibited
nAChRs to dissociate cholinergic- and dopaminergic-driven DA release
and to deﬁne the locus of any adaptations in DA release after lesion.
DHβE (1 μM) was included in bath solutions unless otherwise stated.
Under nAChR inhibition, the frequency dependence of evoked [DA]o
during 5-pulse electrical trains at 5–100 Hz was signiﬁcantly changed
by the lesion (Figs. 1D, E). The range of peak [DA]o evoked by the
lowest to highest frequencies (5–100 Hz) was decreased from 5.5-
fold (non-lesion) to only ~2 fold (lesion) suggesting that changes in
DA neuron ﬁring rate in the parkinsonian brain could generate reduced
moment-by-moment contrast in DA signals.
After lesion, lower frequency trains (5–10 Hz) were relatively better
at releasing DA (normalised to a single pulse, p b 0.05), whereas there
was a trend for higher frequency trains (100 Hz) to be relatively
worse at releasing DA (Figs. 1D, E). Post hoc testing did not ﬁnd this lat-
ter effect to be signiﬁcant, but because of the large spread of data and
degrees of freedom due to themultiple frequencies in the experimental
design, we probed this effect further in separate experiments at 100 Hz.
Using trains of varying length (2–9 pulses, 100 Hz), we conﬁrmed that
at this high frequency, [DA]o was relatively lower in lesioned than
non-lesioned sites (Fig. 1F). Overall, these data show that the sensitivity
of DA release to dynamic activity in DA axons is impaired in release sites
that remain after a lesion.Fig. 2. Paired-pulse ratios at 10 ms reveal increased Pr. A, Plot of [DA]o evoked by the sec-
ond (P2) versus the ﬁrst (P1) of two pulses in a pair, at an IPI of 10 ms, shows an inverse
relationship indicating that P2 is inversely related to initial Pr (linear regression R2=0.48;
F(1,33) = 30.9, p b 0.001; n= 35 sites from 35 animals). B, Mean P2 ± SEM decreases
as inter-pulse interval increases (two-way ANOVA, data transformed to normality
λ = 0.67: F(4,24) = 48.3, p b 0.001) but P2 at 10 ms is reduced in lesion (IPI ∗ lesion
F(4,24) = 5.5, p b 0.005; **p b 0.005 lesion versus non-lesion Fisher's LSD test at
10 ms, non-lesion n = 3 experiments from 3 animals; lesion n = 5 experiments from 5
animals). C, At an IPI of 100 ms, [DA]o at P2 is not related to P1 (linear regression, R2 =
0.07; F(1,33) = 2.5, p N 0.1; n = 35 sites from 35 animals). All data are in the presence of
nAChR antagonist DHβE (1 μM).Paired-pulse studies indicate loss of short-term facilitation and an increase
in Pr after 6-OHDA lesion
A relative increase in [DA]o at lower frequencies, often called ‘up-
take-limited’ frequencies, is an expected consequence of the reduced
densities of DA axons and uptake transporters (DAT) in the striatum fol-
lowing a lesion. A reduction in DAT density will reduce the rate of DA
uptake at all substrate concentrations, allowing greater residual [DA]o
and summation at longer interpulse intervals (IPIs) (Benoit-Marand
et al., 2000; Chergui et al., 1994; Suaud-Chagny et al., 1995). However,
at higher frequencies, a relative impairment in [DA]o is not predicted
by reduced DAT density alone, suggesting that the DA release process
is also altered in these neurons (note that such changes in release ma-
chinery would be expected to impact all frequencies but the effects
will be more visible at ‘release-limited’ frequencies where effects of re-
duced uptake are less of a confound). To separate the contributions of
altered release from altered summation/uptake, we used paired-pulse
stimulations to explore the dynamics of DA release and assess Pr. At
classical, amino acid synapses when paired pulses are delivered with
short inter-pulse intervals (typically b50 ms), the initial Pr determines
release by the ﬁrst pulse (P1 release) and is inversely related to release
at the second pulse (P2 release). Therefore by determining P2 release as
a function of P1 release (known as the paired-pulse ratio, PPR), insights
into initial Pr for DA can be gained.
We ﬁrst identiﬁed the relationship between P2 and P1 for DA release
at a range of release sites in intact striatum (IPI 10 ms). P2 release
(expressed as a percentage of P1) varied inversely with P1 release
across sites (Fig. 2A), conﬁrming that DA release at a subsequent pulse
is an inverse predictor of initial Pr. We next explored the effect of the le-
sion, using a range of inter-pulse intervals (10–200 ms) to explore dy-
namic changes in Pr for a range of frequencies (5–100 Hz). For amino
acid transmitters and DA, P2 release normally equals or exceeds P1 re-
lease (short-term facilitation) at intervals of 50ms or less and decreases
as interpulse interval increases (100–200 ms) when facilitation gives
way to short-term depression (Dobrunz and Stevens, 1997; Regehr,
2012; Rice and Cragg, 2004; Thomson, 2000). We conﬁrmed a similar
relationship here for [DA]o in non-lesioned striatum (Fig. 2B). However,
lesioned striatum differed signiﬁcantly: there was a signiﬁcant loss of
paired-pulse facilitation at the shortest IPI (10 ms) (Fig. 2B) suggestive
of an underlying increase in initial Pr. Loss of facilitation would accountfor the reduced [DA]o observed during high frequency trains seen in
Fig. 1.
Although there was a marked loss of facilitation/increase in Pr at an
IPI of 10 ms, there was no difference between lesioned and non-
lesioned striata in P2 release seen at IPIs longer than 10 ms. These ﬁnd-
ings could be explained by two possibilities: either that P2 is inversely
related to Pr at very short IPIs only (~10 ms) – and can therefore only
be used to predict Pr accurately at this IPI – or that a loss of facilita-
tion of P2 is not reﬂective of increased Pr, but of some other change
(e.g., loss of short-term facilitatory mechanisms). To address the
Fig. 3. Cocaine recapitulates the altered DA release proﬁle seen in a lesion but through a
different mechanism. A, Mean peak [DA]o ± SEM vs frequency (5p) in cocaine
(chequered) vs control (ﬁlled) expressed as % of peak [DA]o evoked by 1p in each condi-
tion, n = 6 experiments from 3 animals. Note similarity to Fig. 1E. Two-way ANOVA:
drug ∗ frequency F(3,15) = 65.3, p b 0.001; *p b 0.05 naïve versus cocaine, Fisher's LSD
test. B, Mean peak [DA]o ± SEM vs pulse number (100 Hz) in non-lesion, lesion and co-
caine-treated non-lesioned striatum expressed as % of peak [DA]o evoked by 1p in each
condition. Two-way ANOVA: F(2,10) = 14.6, Treatment p b 0.01; #p b 0.05 main effect
of cocaine versus non-lesion; **p b 0.005 main effects lesion versus non-lesion. For
each group, n = 5 experiments from 5 animals C, Mean peak [DA]o ± SEM vs
[Ca2+]o in lesion, non-lesion and cocaine-treated non-lesioned sites. [Ca2+]
F(3,42) = 2.7, p b 0.001, [Ca2+] ∗ treatment F(1,14) = 4.7, p b 0.05; #p b 0.05 main effect
of cocaine versus both lesion and non-lesion, *p b 0.05, lesion n = 5 experiments from 5
animals; for all other groups n = 6 experiments from 6 animals.
266 K.A. Jennings et al. / Neurobiology of Disease 82 (2015) 262–268former possibility we explored the relationship between P1 and P2
across a range of release sites in intact striatum with a longer IPI of
100 ms. Our data show that although P2 varies inversely with P1 at
release sites for short intervals of 10 ms (see Fig. 2A), by contrast P2
does not vary with P1 at the longer interval of 100 ms (Fig. 2C). These
data identify that P2 delivered only at very short IPI is an index of DA
Pr, and support the hypothesis that loss of short-term facilitation in a le-
sion is due to an increase in Pr. These data suggest that a lesion leads to
changes in dynamic DA signals through a combination of reduced up-
take, enhanced Pr and loss of short-term facilitation.
DAT inhibition recapitulates aspects of altered DA release caused by
6-OHDA lesion
To further verifywhether simultaneous changes in uptake and Pr de-
scribed above could combine to cause the observed changes in dynamic
availability of [DA]o, we compared the effects of a lesion to those of
cocaine since this drug has been shown to both inhibit DA uptake and
enhanceDA releasability (Kile et al., 2010; Venton et al., 2006). Similarly
to the lesion, cocaine (5 μM) modiﬁed the frequency dependence of
evoked [DA]o: low frequencies were relatively better at evoking [DA]o
(normalised to single pulse release) whilst higher frequencies released
relatively less [DA]o (Fig. 3A). During trains of 2–9 pulses at 100 Hz,
cocaine reduced evoked [DA]o (normalised to a single pulse) compared
to cocaine-free sites and the resulting relationship between train length
and [DA]o was indistinguishable from that induced by a lesion (Fig. 3B).
In paired-pulse experiments, a similar trendwas observed,with cocaine
causing a loss of facilitation comparable to lesion at an IPI of 10ms (data
not illustrated: mean amplitude P2 (% of P1) ± SEM: 174 ± 8%, non-
lesion without cocaine; 94 ± 2%, non-lesion with cocaine; 94± 10% le-
sion without cocaine; IPI ∗ drug ∗ lesion F(4,24) = 5.7, p b 0.005; lesion
versus non-lesionwith cocaine p N 0.19; non-lesionwith cocaine versus
without p b 0.005; data transformed to normality λ= 0.67). However,
despite these similarities between the effects of cocaine and lesion,
their effects appeared to be mediated by different mechanisms. Cocaine
promotes DA release via a synapsin-dependent mechanism, and
knockout of synapsins changes the Ca2+-dependence of DA release
(Kile et al., 2010) suggesting that cocaine might act to change the
Ca2+-dependence of [DA]o. We showed this to be the case (Fig. 3C).
However, lesion by contrast did not change the Ca2+-dependence of
DA release (Fig. 3C) from that seen in cocaine-free, non-lesioned sites.
nAChR activity masks the DA release abnormalities caused by 6-OHDA
lesion
All observations so far weremade in the absence of the confounding
effects of nAChR activation, under nAChR blockade. Therefore, we
explored ﬁnally whether our observed changes to the activity-
dependence of DA signals after a lesion were exacerbated or offset
by concurrent activation of nAChRs. When nAChRs were permitted
to be activated by ACh released by local electrical stimulation
(Exley et al., 2008; Rice and Cragg, 2004; Threlfell et al., 2012),
[DA]o in non-lesioned sites showed only weak dependence on frequen-
cy (Fig. 4A) or pulse number (Fig. 4B) compared towhen nAChRs are in-
active (cf. Fig. 1). Furthermore, these relationships did not differ
signiﬁcantly between lesioned and non-lesioned sites (Fig. 4), indicat-
ing that the underlying changes to DA release resulting from a lesion
are masked during concurrent nAChR activation.
Discussion
We show that DA release remaining in the parkinsonian brain is dys-
regulated, with decreased short-term facilitation reﬂecting an increased
Pr. This altered release combines with reduced uptake to lessen the con-
trast betweenDA signals evoked by differentﬁring frequencies. Further-
more, activation of nAChRs by ACh masks these adaptations, with nosigniﬁcant difference in the activity-dependence of DA signals between
lesioned and non-lesioned striata when nAChRs are active.
Impaired DA signal contrast after parkinsonian lesion
Our data indicate that, when nAChRs are inactive, the contrast be-
tween DA signals evoked by low versus high frequencies of DA neuron
Fig. 4. nAChR activity masks effects of a lesion. A, Mean peak [DA]o ± SEM vs frequency
(5p) in the absence of nAChR inhibitors, in non-lesioned (unﬁlled) vs lesioned striatum
(ﬁlled) expressed as % of peak [DA]o evoked by 1p in each condition. Two-way ANOVA:
Frequency, F(3,18) = 16.1; p b 0.001; data transformed for normality λ = −1.55, for
each groupn=7experiments from7 animals B, Mean peak [DA]o± SEMvspulse number
(100 Hz) in the absence of nAChR inhibitors in non-lesioned (unﬁlled) vs lesioned stria-
tum (ﬁlled) expressed as % of peak [DA]o evoked by 1p in each condition. Two-way
ANOVA: no signiﬁcant difference, for each group n = 6 experiments from 6 animals.
267K.A. Jennings et al. / Neurobiology of Disease 82 (2015) 262–268activity will be reduced in PD. Our ﬁndings corroborate and build
further on the previous ﬁnding that DA release is impaired after a
parkinsonian lesion during high frequency stimulus trains in vivo
(Bergstrom and Garris, 2003), and suggest a novel mechanism to ex-
plain this impairment.We show a dysregulation of DA signals that is ex-
pected to be particularly prevalent during periods of nAChR inactivity.
Such periods of inactivity could feasibly arise during the pauses in ChI
activity that are seen in vivo (Aosaki et al., 1994, 1995; Cragg, 2006;
Morris et al., 2004). Pauses in ChI activity are acquired during motor
learning and show coincidence with phasic activity in DA neurons
(e.g., Morris et al., 2004), which could have relevance for action selec-
tion and initiation. Our data predict that reduced nAChR activation
due to a ChI pause will impair most profoundly the DA signals released
by high frequency activity in DA neurons.
High frequency activity is observed in most dopamine neurons in
VTA and SNc (Schultz, 1998). Traditionally, high frequency activity in
dopamine neurons has been associated exclusively with reward-
processing and decision-making. However, recent evidence has shown
that high frequency activity in SNc neurons in particular correlates
with the onset and offset of learned action sequences (Jin and Costa,
2010) andmay be important for habit formation, a process that is dorsal
striatum-mediated (Wang et al., 2011). Therefore, our observation of al-
tered activity-dependence of dopamine may have signiﬁcance for both
decision-making processes and for motor function, most importantly,
for the movement deﬁcits seen in PD. It will be important to establish
empirically whether the behavioural consequences of DA released by
higher DAneuronﬁring frequencies are impaired in PD and if so, wheth-
er such impairments can be rescued by changing ChI and/or nAChR
activity.Enhanced DA Pr after 6-OHDA lesion
Historically, studies have typically assumed that DA release is invari-
ant with pulses within a train and have not resolved subsecond changes
to DA release in models of PD (Bezard and Gross, 1998; Bezard et al.,
2000; Garris et al., 1997). However, DA release is not constant during
a train of action potentials but is subject to moment-by-moment
short-term plasticity of release probability (Cragg, 2003; Montague
et al., 2004; Rice and Cragg, 2004). We revealed a relationship between
DA release probability and short-term plasticity of release that is visible
over short timescales only (on the order of 10 ms) and not over longer
timescales (on the order of 100 ms). Furthermore, using subsecond
trains and pairs of pulses we reveal for the ﬁrst time that a DA lesion
causes loss of facilitation of DA release at short inter-pulse intervals,
which indicates an increased Pr from surviving DA release sites in dorsal
striatum. Note thatwhilst our data suggest that loss of facilitation is like-
ly only to be evident at the high ﬁring frequencies not commonly re-
ported for DA neurons, the mechanisms underpinning this and
enhanced Pr are likely to have consequences for DA release at all spon-
taneous ﬁring frequencies.
Experiments with cocaine showed that DAT inhibitionwas followed
by changes to frequency dependence and DA Pr that are distinct from
simple increases in extracellular summation of DA. These ﬁndings cor-
roborate previous ﬁndings that cocaine increase DA release in addition
to reducing uptake (Kile et al., 2010; Venton et al., 2006). However,
although cocaine and a DA lesion caused similar effects here, the mech-
anisms were not the same. Cocaine modiﬁed the dependence of DA re-
lease on [Ca2+] but lesion did not. Changes in the distribution of vesicle
pools can regulate Pr at CNS synapses (e.g., Regehr, 2012) and we have
recently shown that changes to vesicle clustering accompany changes to
DA Pr in an alpha-synuclein-overexpressingmousemodel of PD (Janezic
et al., 2013). Altered vesicular regulation is a candidate mechanism for
altered DA Pr here in a late stage DA lesion that should be addressed
in future studies.
One previous study found evidence of altered release in a PDmodel,
reporting enhanced sustainability of release during long, fatiguing
stimuli (Bergstrom et al., 2011). The authors suggested that loss of a
long-term depression (LTD) component (Montague et al., 2004)
underpinned these observations. We show here rather that Pr is in-
creased and short-term facilitation is impaired. This mechanism might
preserve release pools and sustain release over longer time frames. In
support of this relationship between our ﬁndings and those of enhanced
sustainability of DA release, are theﬁndings that inhibition of DA uptake
recapitulated both the long-term sustainability of release (Bergstrom
et al., 2011) and the short-term impairment in high frequency DA
release shown here. It is not yet evident however whether the most
desirable outcome of an improved therapy for PD would be to reverse
the deﬁcit in high frequency DA signalling or to promote the long
termmaintenance of DA release, but the potential competition between
these two factors is important to keep in mind.
nAChRs reverse activity dependence deﬁcits after a 6-OHDA lesion?
The changes we observed in activity-dependence of DA release after
a partial 6-OHDA lesion were exposed in the absence of nAChR-
regulation of DA. However, when nAChRs were not blocked, and were
activated by local electrical stimulation of DA axons and ChIs, the
activity-dependence of DA release was not different between lesioned
and non-lesioned striata. Thus, abnormalities in DA Pr could be masked
by nAChR activation which restores DA activity-dependence to a pre-
lesion state. This ismost likely because nAChRs very powerfully increase
the apparent DA Pr by ~100–300% (Rice and Cragg, 2004; Threlfell et al.,
2012; Zhang and Sulzer, 2004; Zhou et al., 2001). Such a powerful effect
is expected to dominate and eclipse other mechanisms located in DA
axons that regulate DA Pr, increasing Pr maximally and causing a ceiling
effect which ensures that no difference in signalling is detectable
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activity might therefore determine the extent of impairment to DA re-
lease at any given moment. Our data suggest that activity-dependence
will bemost impaired when nAChR activation is minimal, which should
occur when ChIs pause. Our ﬁndings may appear on ﬁrst sight to be
contradictory to the widely held view that anti-cholinergic drugs are
beneﬁcial for PD. However, it should be noted that anti-cholinergic
therapies act at muscarinic receptors, whilst the data presented here
provide further support for nicotinic receptor activation as therapeutic
targets in PD (Quik et al., 2009). Future experiments should explore
our results during in vivo patterns of activity and determine whether
activating nAChRs is desirable for behaviour.
Conclusions
In summary, we show for the ﬁrst time that besides the profound
deﬁcit in DA levels in PD, a parkinsonian lesion causes a blunted dynam-
ic range of DA release, which is underpinned by the loss of short-term
facilitation and increased Pr of remaining DA. This difference in dynamic
availability of DA is minimised by nAChR activation. These ﬁndings
reveal that high frequency DA function in particular is impaired in the
parkinsonian brain and suggest that striatal nAChRs might be targets
for future PD therapies.
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